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Several reports support the concept that bile acids may be cytotoxic during cholestatic
disease process by causing mitochondrial dysfunction. Here we report additional data and
findings aimed at a better understanding of the involvement of the permeability transition
pore (PTP) opening in bile acids toxicity. The mitochondrial PTP is implicated as a
mediator of cell injury and death in many situations. In the presence of calcium and phos-
phate, chenodeoxycholic acid (CDCA) induced a permeability transition in freshly isolated
rat liver mitochondria, characterized by membrane depolarization, release of matrix cal-
cium, and osmotic swelling. All these events were blocked by cyclosporine A (CyA) and
the calcium uniporter inhibitor ruthenium red (RR). The results suggest that CDCA
increases the sensitivity of isolated mitochondria in ûitro to the calcium-dependent induction
of the PTP.
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INTRODUCTION
Liver diseases such as cholestasis are a significant clinical problem, but the cellular
mechanisms disturbed during these pathophysiological processes are still contro-
versial. Retention of toxic, hydrophobic bile acids occurs during cholestasis [1]. The
accumulation of toxic bile acids results in chemical damage to hepatocytes and is
thought to be responsible, at least in part, for liver injury during cholestasis [2].
The tendency to cause cytotoxicity has been correlated with bile acids hydro-
phobicity [3, 4]. Chenodeoxycholic acid (CDCA), a primary bile acid most impli-
cated in cholestatic liver injury, is known to be directly cytotoxic for hepatocytes
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[5]. Hepatic tissue concentrations of CDCA increase 20-fold during cholestasis and
are greater than those of other toxic bile acids [6].
Impairment of mitochondrial function seems to be a central biochemical path-
way of cell dysfunction during the cholestatic disease process. ATP depletion
observed after addition of glycochenodeoxycholate, even in the absence of a gly-
colytic substrate, suggests disturbing of mitochondrial function [7]. Long-term chol-
estasis caused by bile duct ligation is known to lead to impaired hepatic
mitochondrial function in the rat [8] and enlarged, swollen mitochondria are
observed in histopathologic sections obtained from this model of extrahepatic chol-
estasis [9]. Additionally, bile acid-induced decrease on state 3 respiration in isolated
rat liver mitochondria [10, 11] and in digitonin-permeabilized cells [7], has been
reported. Since mitochondria are provided with a variety of bioenergetic functions
mandatory for the regulation of intracellular aerobic energy production and electro-
lyte homeostasis, impairment of mitochondrial function by bile acids may have dras-
tic consequences on cellular function through the perturbation of the bioenergetic
charge and balance of the cell.
Mitochondria are also involved in cell demise through opening of the mito-
chondrial permeability transition pore (PTP). PTP induction is implicated in the
mechanism of cell killing by a number of agents including heavy metals, pesticides,
and selected pharmaceuticals [12, 13]. The transition is characterized by a calcium-
dependent increase in the non-specific permeability of the inner mitochondrial mem-
brane accompanied by the depolarization of membrane potential and mitochondrial
swelling. Induction of the transition requires adequate matrix calcium and phosphate
and is inhibited by extramitochondrial calcium and acidification of the mitochondr-
ial matrix [14–16]. Cyclosporine A (CyA) is a potent inhibitor of the permeability
transition [17].
Recent data have reported the induction of the PTP as a mechanism of cytotox-
icity of bile acids [11, 18, 19]. The mechanism by which bile acids promote the onset
of PTP remains unclear. The present study attempted to gain further insight into
CDCA effects on the mitochondrial permeability transition, in order to better eluci-
date possible mechanisms of action.
MATERIALS AND METHODS
Chemicals
CDCA, used as ethanolic solution was purchased from Sigma Chemical Co.
(St. Louis, MO). Cyclosporine A was a generous gift from Novartis Pharma AG
(East Hanover, NJ). All other chemicals were of the highest grade of purity commer-
cially available.
Isolation of Mitochondria
Mitochondria were isolated from liver of male Wistar rats by conventional
methods [20] with slight modifications. Homogenization medium contained 250 mM
sucrose, 10 mM Hepes (pH 7.4), 0.5 mM EGTA, and 0.1% fat-free bovine serum
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albumin. EGTA and bovine serum albumin were omitted from the final washing
medium, adjusted at pH 7.4. The mitochondrial pellet was washed twice, suspended
in the washing medium, and immediately used. Protein content was determined by
the biuret method [21] calibrated with bovine serum albumin.
Membrane Potential (∆Ψ) Measurements
The mitochondrial transmembrane potential was estimated using an ion-selec-
tive electrode to measure the distribution of tetraphenylphosphonium (TPP+)
according to previously established methods [22, 23]. The reference electrode was
AgAgCl2. The incubation medium contained 200 mM sucrose, 10 mM Tris-Mops
(pH 7.4), 1 mM KH2PO4 , and 10 µM EGTA supplemented with 2 µM rotenone and
0.5 µgml oligomycin. Mitochondria (0.5 mg) were suspended with constant stirring,
at 25°C, in 1 ml of the standard incubation medium supplemented with 3 µM TPP+
and were energized by adding succinate to a final concentration of 5 mM. The distri-
bution of TPP+ was allowed to reach a new equilibrium (ca. 2 min) before making
any further addition. The electrode was calibrated with TPP+ assuming Nerstian
distribution of the ion across the synthetic membrane. A matrix volume of 1.1 µl
mg protein was assumed.
Measurement of the Mitochondrial Permeability Transition
Mitochondrial swelling was estimated by changes in light-scattering as moni-
tored spectrophotometrically at 540 nm [24]. The reaction was stirred continuously
and the temperature maintained at 25°C. The experiments were started by the
addition of 1 mg of mitochondria to a final volume of 2 ml of the standard incu-
bation medium, supplemented with 2 µM rotenone, 0.5 µgml oligomycin, and
5 mM succinate. Calcium (20 µM CaCl2) was added prior to all other compounds.
Measurement of Mitochondrial Calcium Fluxes
The accumulation and release of calcium by isolated rat liver mitochondria was
determined using a calcium-sensitive fluorescence dye, calcium green-5N [25]. The
reactions were carried out at 25°C, in 2 ml of the standard incubation medium,
supplemented with 2 µM rotenone, 0.5 µgml oligomycin, and 0.1 µM calcium green-
5N. Mitochondria (0.4 mg) were suspended with constant stirring. Fluorescence (ex.,
505 nm; em., 531 nm) was monitored continuously for an additional 1.5 min prior
to adding calcium (CaCl2) to a final concentration of 5 µM. Fluorescence was moni-
tored continuously for an additional 3 min, at which time 8 mM succinate was added
to the suspension. At each experiment, fluorescence was monitored for an additional
10 min before stopping the reaction with excess EGTA. Calcium fluxes are expressed
as relative fluorescence units (RFU). At the concentration examined, CDCA did not
interfere with the experimental assay.
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RESULTS
Figure 1 illustrates the effect of CDCA on membrane potential (∆Ψ ), in hepatic
mitochondria energized with succinate. Upon addition of calcium (15 µM) to mito-
chondria, a transient depolarization of membrane potential occurred, followed by
repolarization to the initial resting membrane potential. Subsequent addition of
50 µM CDCA resulted in an immediate decrease of membrane potential, which was
not prevented by CyA. Calcium-loaded mitochondria, in the presence of CDCA,
were incapable of sustaining membrane potential and underwent a gradual depolar-
ization over time. This is the result of PTP induction and the associated loss of
regulation of transmembrane ionic gradients. Pretreatment with both CyA and
ruthenium red (RR) prevented this CDCA-induced dramatic depolarization (Fig. 1).
Mitochondria possess a finite capacity for accumulating calcium before under-
going the calcium-dependent PTP. Figure 2 illustrates the results achieved when we
Fig. 1. Effect of chenodeoxycholic acid (CDCA) on mitochondrial trans-
membrane potential (∆Ψ ). Mitochondria (0.5 mg) were incubated in 1 ml
of the standard incubation medium supplemented with 2 µM rotenone,
0.5 µgml oligomycin, and 3 µM TPP+ and energized with 5 mM succinate.
Calcium was added at a final concentration of 15 µM. Where indicated (first
arrow), 1 µM CyA or 1 µM ruthenium red (RR) were included in the reac-
tion medium prior to addition of 50 µM CDCA. The traces are typical of
several independent experiments with four different mitochondrial
preparations.
Chenodeoxycholate in Rat Liver Mitochondria 77
follow mitochondrial swelling as the indicator for induction of the PTP by CDCA.
As we reported previously [11], calcium-loaded, succinate-energized rat liver mito-
chondria underwent a permeability transition, as reflected by the decreased
absorbance at 540 nm, upon addition of CDCA. In all cases, the induction of mito-
chondrial swelling by CDCA required calcium and was inhibited completely by prior
addition of CyA (Fig. 2). Furthermore, PTP induction by CDCA was also prevented
upon preincubation of calcium-loaded mitochondria with 1 µM RR (Fig. 2). No
swelling was observed in control mitochondria following calcium addition.
Mitochondrial calcium homeostasis was also adversely affected by CDCA.
Unlike control mitochondria, which accumulated all of the added calcium and
retained it for the entire period monitored, after addition of CDCA, mitochondria
released all the accumulated calcium (Fig. 3).
The protective effect of CyA against CDCA-induced mitochondrial calcium
release was assessed to evaluate the involvement of PTP induction in this phenom-
enon. Indeed, including CyA prior to CDCA, completely prevented mitochondrial
calcium release. Similar results were achieved by adding RR at the same time as
CyA (data not shown), which is what would be predicted from the results of mem-
brane potential and swelling experiments.
Furthermore, adding RR during the course of CDCA-induced calcium release
prevented the release of all the accumulated calcium (Fig. 3). It seems likely that
RR inhibited the net reaccumulation of released calcium from mitochondria,
implicating the electrophoretic uniport in the reuptake of the released calcium.
Fig. 2. Effect of chenodeoxycholic acid (CDCA) on PTP induction. The incubation medium
(final volume 2 ml at 25°C) contained 200 mM sucrose, 10 mM Tris-Mops (pH 7.4), 1 mM
KH2PO4 , and 10 µM EGTA supplemented with 2 µM rotenone, 0.5 µgml oligomycin, and
5 mM succinate. The experiments were started by the addition of 1 mg of mitochondria (not
shown). Calcium (20 µM) was added prior all other compounds. Where indicated (first arrow),
1 µM CyA, or 1 µM ruthenium red (RR) were included in the reaction medium prior to 50 µM
CDCA. The traces are typical of several independent experiments with four different mito-
chondrial preparations.
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Fig. 3. Chenodeoxycholic acid (CDCA)-induced mitochondrial calcium
release. Mitochondria (0.4 mg) were incubated in 2 ml of the standard incu-
bation medium prior to calcium (5 µM). Calcium fluxes, expressed as relative
fluorescence units (RFU), was recorded for an additional 13 min. When indi-
cated, CyA (0.4 µM) or ruthenium red (RR; 0.4 µM) was added prior or after,
respectively, to CDCA (20 µM). Excess EGTA was added at the end of the
experiment. The traces are typical of several independent experiments with
three different mitochondrial preparations. An upward pen deflection is indica-
tive of calcium release.
DISCUSSION
In a previous report, we indicated that mitochondria were likely the subcellular
target for bile acids hepatotoxicity [11]. It was suggested that a perturbation of
mitochondrial bioenergetics was involved in the cytotoxic action of these com-
pounds. The present study provides new data useful to understand the mechanisms
whereby bile acids elicit liver injury. Data obtained with isolated rat liver mitochond-
ria suggest that CDCA, a primary bile acid most implicated in cholestatic liver
injury, may alter the regulation of the cyclosporine A-sensitive permeability tran-
sition pore.
PTP opening is widely accepted to be an early event in pathophysiology of cell
death [26]. It is characterized by mitochondrial membrane depolarization, mito-
chondrial calcium release, and an increase in non-specific permeability of the inner
membrane to low-molecular-weight solutes, leading to mitochondrial swelling and
inhibition of oxidative phosphorylation. The PTP is suggested to be composed of a
complex of distinct proteins, which accounts for the coordinated regulation of the
pore by assorted factors, including several chemically diverse inducing agents [27].
Some key features of the PTP are that it has a strict requirement for matrix calcium
and is selectively inhibited by CyA [17].
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The detection of membrane potential loss and osmotic swelling, after adding
CDCA to calcium-loaded isolated mitochondria, suggests the sensitization of mito-
chondria to PTP opening, probably at the level of calcium-binding sites on the
matrix side of the membrane. Associated with induction of mitochondrial swelling
by CDCA, was a pronounced loss of matrix calcium. The sensitivity of PTP acti-
vation to CyA was used to confirm its involvement in the observed disruption of
mitochondrial calcium homeostasis. Complete inhibition of both mitochondrial
swelling and matrix calcium release by CyA, suggests a selective effect of CDCA on
this specific channel. The fact that CyA completely prevented the reduction in maxi-
mum calcium accumulation by mitochondria, in the presence of CDCA, indicates
that the lower capacity to accumulate calcium represents a stimulation of calcium
release rather than inhibition of calcium uptake. This is further evidenced by the
success of preventing the observed CDCA effects by using ruthenium red.
Results provide evidence for the opening of this pore within a subpopulation
of hepatic mitochondria, upon adding CDCA. At the level of a single mitochondrion
the PTP opening is an all-or-nothing event. The kinetics observed in light-scattering
experiments, i.e., on a time scale of minutes, reflect therefore the propagation of
the transition through the population of mitochondria [27]. PTP-induced loss of
transmembrane potential will also lead to the efflux of calcium which the mitochond-
ria had originally been loaded. The released calcium may be taken up by still-coupled
mitochondria, which would also undergo CDCA-induced PTP opening. When the
uptake uniport was inhibited with RR, calcium was not reaccumulated. The ability
to reaccumulate the released calcium indicates that the mitochondria were capable
of establishing a membrane potential sufficient to support the electrophoretic cal-
cium uptake uniport [28]. The preventative action of RR therefore reflects differing
sensitivities among subpopulations of mitochondria.
In summary, our data provide further evidence for the permeability transition
of the membrane of individual mitochondria caused by CDCA, in ûitro. We conclude
that this may be an important step within the cascade of events which induce break-
down of mitochondria and cellular function, involved in the cholestatic disease
process. The precise mechanism by which CDCA interferes with regulation of the
pore has yet to be defined.
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